Development of C-SMART: Cognitive Strategies, Mindfulness, and Rehabilitation Therapy for Patients With Glioma

Sponsor
Virginia Commonwealth University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05984667
Collaborator
American Psychological Foundation (Other)
16
1
7

Study Details

Study Description

Brief Summary

The primary aims of this mixed-methods trial are to test the feasibility and acceptability of the novel Cognitive Strategies, Mindfulness, and Rehabilitation Therapy (C-SMART) delivered via telehealth to patients with glioma and mild neurocognitive disorder (mNCD).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: C-SMART
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
16 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Development of C-SMART: Cognitive Strategies, Mindfulness, and Rehabilitation Therapy for Patients With Glioma
Anticipated Study Start Date :
Aug 31, 2023
Anticipated Primary Completion Date :
Mar 31, 2024
Anticipated Study Completion Date :
Mar 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: C-SMART

C-SMART intervention will be provided via telehealth. Participants will complete in-person neurocognitive testing (baseline, post-intervention) as well as surveys (baseline, post-session, post-intervention) via secure email link. Exit interviews will be conducted by Zoom.

Behavioral: C-SMART
The C-SMART intervention includes approximately 8 individual therapy sessions, each approximately 60 minutes in length, delivered weekly. C-SMART intervention components include cognitive rehabilitation and mindfulness training.

Outcome Measures

Primary Outcome Measures

  1. Determine feasibility of C-SMART recruitment [10 months]

    As evidenced by rates of participant screening, eligibility, and consent

  2. Determine feasibility of C-SMART - Data collection procedures [10 months]

    As evidenced by the number of participants that complete the neurocognitive assessments pre- and post-intervention

  3. Determine acceptability of C-SMART intervention - Attendance [10 months]

    As evidenced by the attendance rate at intervention sessions

  4. Determine feasibility of C-SMART - Retention Rate [11 months]

    As evidenced by the number of patients that complete post-intervention measures

  5. Determine acceptability of C-SMART intervention - Satisfaction [10 months]

    After each intervention session, participants will be sent a link for a brief post-session satisfaction survey via secure email link. In this survey, participants will rate 1) topic applicability; 2) perceived benefit of session; 3) comfort with interventionist(s); 4) overall satisfaction and 5) likelihood of recommending the program to others. Responses are ranked on a Likert-type scale from 1 being "Not at all" to 5 being "A great deal". Higher scores indicate greater satisfaction with the intervention session.

  6. Determine acceptability of C-SMART intervention - Satisfaction - Recommendation [10 months]

    As evidenced by the number of patients that would recommend the intervention to others

  7. Optimization of C-SMART research procedures [8 months]

    The number of participants that complete exit interviews will be audio recorded and transcribed verbatim. The PI and a second independent coder will separately review each transcript to identify common themes and develop a coding framework of free responses. All results will be reviewed for agreement and comparison to the raw data, and discrepancies will be resolved through discussion with the PI until reliability is reached (Kappa>.80)

Secondary Outcome Measures

  1. Determine feasibility of C-SMART research procedures - Patient reported outcome completion [10 months]

    Feasibility of research procedures will be assessed by the number of participants that complete the baseline survey, post-session survey, and the post-intervention survey.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adults with a glioma diagnosis confirmed by histology

  • At least one domain of neurocognitive function ≥ 1.5 SD below estimate premorbid functioning

  • Karnofsky' Performance Status (KPS) score ≥ 80

  • ≥ 1 month out of radiation therapy

  • Ability to read, speak, and understand English

Exclusion Criteria:
  • Inability to attend virtual sessions

  • Inability to understand and provide informed consent

  • Presence of clinically significant insomnia

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Virginia Commonwealth University
  • American Psychological Foundation

Investigators

  • Principal Investigator: Sarah E Braun, PhD, Virginia Commonwealth University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Virginia Commonwealth University
ClinicalTrials.gov Identifier:
NCT05984667
Other Study ID Numbers:
  • MCC-22-20126
First Posted:
Aug 9, 2023
Last Update Posted:
Aug 16, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Virginia Commonwealth University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2023